Loading...
Loading...
Piper Jaffray analyst David Amsellem published a report on Supernus Pharmaceuticals
SUPN that reiterated its Overweight rating and lowered the price target from $15 to $14 per share.
Piper Jaffray reported that, “Supernus reported a 4Q12 net loss per share of ($0.51) and finished 2012 with $92M in cash on hand. Management provided favorable color regarding the recent Oxtellar XR launch, noting particularly strong managed care access for the product. With one product now on the market and another launch (i.e., Trokendi XR, which should launch in 3Q13) on the horizon (each with sales potential in excess of $150M in our view), plus an advancing pipeline focused on ADHD/psychiatry, SUPN shares remain attractive in our view in the context of a market cap of near $200M.”
Shares of Supernus Pharmaceuticals closed at $6.90 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in